Diabetes Drug 'Lyxumia' gets Nod for Sale in Europe
Lyxumia is an injectable drug manufactured by Sanofi, a French pharmaceutical company, to treat type 2 diabetes.
The drug is once-a-day diabetes injection along with the standard diabetes medications. It is prescribed for those diabetics who are unable to control their blood sugar level. The drug was approved after 11 clinical trials covering over 5,000 type 2 diabetics. It was shown to have a positive effect on lowering and regulating blood sugar level as well as a reduction in body weight.
"With the European approval of Lyxumia, we now have a simple new tool to help patients with type 2 diabetes further reduce HbA1c, with the benefit of weight loss and limited risk of hypoglycaemia. This well-tolerated therapy is of specific interest to patients who are on oral treatments and/or basal insulin and do not manage to maintain their HbA1c targets. With a single daily injection and only one step to maintenance dose, Lyxumia is a positive addition to the Sanofi portfolio, and represents another step forward in our efforts to advance scientific excellence and develop new therapeutic solutions that improve outcomes for people with diabetes, an area of significant unmet medical need," Pierre Chancel, senior vice president, Global Diabetes at Sanofi, said in a company news release.
The red blood cells are made of hemoglobin which in association with glucose forms HbA1c otherwise known as a glycosylated hemoglobin molecule. Lyxumia when administered once a day along with other medications will help patients maintain the HbA1c level in the blood, thus helping the type 2 diabetics to lead a better quality of life.